

Heart Failure POC & LOC Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Test Type (Genomic Testing, Metabolomic Testing, Proteomic Testing), By Technology (Array-based Systems, Microfluidics), By End-user (Assisted Living Healthcare Facilities, Clinics, Home, Hospitals, Laboratory), By Region, By Competition Forecast & Opportunities, 2018-2028F

<https://marketpublishers.com/r/HFCB299483C1EN.html>

Date: November 2023

Pages: 189

Price: US\$ 4,900.00 (Single User License)

ID: HFCB299483C1EN

Abstracts

Global Heart Failure POC & LOC Devices Market has valued at USD 84.54 million in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.86% through 2028. The potential for enhancing disease diagnosis, particularly in terms of affordability, processing capacity, user-friendliness, and analysis, is notably high due to the downsizing of lab-on-a-chip (LOC) technology. The market is projected to be influenced by research and development efforts aimed at creating innovative LOC-based tests for the detection of cardiovascular disease (CVD).

Key Market Drivers

Technological Advancements

The healthcare industry is undergoing a technological revolution, and this transformation is significantly impacting the field of cardiac care. Among the notable advancements, Point-of-Care (POC) and Lab-on-a-Chip (LOC) devices are playing a pivotal role in the diagnosis and management of heart failure.

One of the most striking technological advancements in healthcare is the miniaturization of diagnostic tools. POC and LOC devices have become increasingly compact and portable, allowing for quick and efficient testing anywhere, from hospitals and clinics to remote locations. This portability improves patient access to heart failure diagnostics and ensures rapid interventions, which can be crucial in critical situations.

Technological breakthroughs have led to the development of POC and LOC devices with heightened sensitivity and specificity in detecting heart failure biomarkers. These devices can detect subtle changes in cardiac markers, providing clinicians with valuable information for early diagnosis and intervention. As a result, patients can receive timely treatment, potentially improving their prognosis and quality of life.

In the age of digital healthcare, connectivity is a game-changer. Advanced POC and LOC devices are equipped with connectivity features, allowing real-time data transmission to electronic health records and healthcare providers. This seamless integration of data enhances care coordination, enables remote monitoring, and facilitates more personalized treatment plans for heart failure patients.

The integration of AI and machine learning algorithms into POC and LOC devices is another technological milestone. These devices can now analyze complex datasets, identify patterns, and assist healthcare professionals in making more accurate diagnostic decisions. AI-driven diagnostics not only improve the accuracy of heart failure detection but also expedite the process, leading to quicker treatment initiation.

Technological advancements have enabled POC and LOC devices to conduct multiplex testing, which means they can simultaneously analyze multiple cardiac markers from a single sample. This capability allows for a more comprehensive assessment of a patient's cardiac health, reducing the need for multiple tests and streamlining the diagnostic process.

While technological advancements often come with expectations of increased costs, POC and LOC devices have managed to maintain cost-effectiveness. These devices minimize the need for specialized laboratory equipment and reduce the overall healthcare expenditure by providing rapid and accurate results, leading to more efficient resource allocation.

Increasing Prevalence of Heart Failure

Heart failure is a chronic and progressive condition where the heart is unable to pump blood efficiently to meet the body's needs. Its prevalence is on the rise due to several factors. An aging population, sedentary lifestyles, poor dietary habits, and the increasing incidence of other chronic diseases like diabetes and hypertension are contributing to the surge in heart failure cases. As the global burden of heart failure grows, there is a heightened need for accurate and timely diagnosis, paving the way for POC and LOC devices to shine.

Early detection is crucial in managing heart failure effectively. POC and LOC devices provide rapid and convenient methods for diagnosing heart failure, allowing healthcare providers to identify the condition at an earlier stage. Timely intervention and personalized treatment plans can significantly improve patient outcomes and reduce the overall healthcare costs associated with heart failure management.

Traditional diagnostic methods for heart failure often involve time-consuming laboratory tests that can delay diagnosis and treatment. POC and LOC devices offer a solution by delivering quick results, enabling healthcare professionals to make informed decisions promptly. This swift turnaround time can be lifesaving in acute heart failure cases.

In many regions, especially underserved or remote areas, access to advanced healthcare facilities may be limited. POC and LOC devices are portable and user-friendly, making them ideal for deployment in diverse healthcare settings, including rural clinics and ambulances. These devices bridge the gap in access to cardiac diagnostics and ensure that patients receive timely care, regardless of their location.

The economic burden of heart failure on healthcare systems is substantial. Hospitalizations, extended treatments, and recurrent diagnostic tests can escalate costs. POC and LOC devices offer cost-effective solutions by minimizing the need for extensive laboratory testing and reducing hospital admissions. Patients can receive timely diagnosis and monitoring, which can translate into lower healthcare expenses over the long term.

Rising Healthcare Costs

The escalating costs of healthcare are a growing concern globally. As healthcare expenses continue to rise, innovative solutions become crucial for improving patient care while managing financial burdens.

Healthcare costs are a significant concern for governments, insurers, and patients alike.

Chronic diseases, including heart failure, often entail extended hospital stays, repeated diagnostic tests, and specialized treatments. These factors contribute to the soaring costs associated with managing heart failure, which can place a considerable strain on healthcare budgets.

Heart failure POC and LOC devices offer a cost-effective alternative to traditional diagnostic methods. These devices eliminate the need for extensive laboratory tests and reduce the number of hospital admissions, which can be prohibitively expensive. By providing accurate and rapid results, POC and LOC devices help streamline the diagnostic process, resulting in significant cost savings for healthcare systems.

The ability to diagnose heart failure quickly with POC and LOC devices enables healthcare providers to initiate treatment promptly. Early interventions can prevent the progression of heart failure to more severe stages, potentially reducing the need for costly interventions such as heart transplants or prolonged hospital stays. This not only improves patient outcomes but also minimizes healthcare expenditures.

Rising healthcare costs can place a significant financial burden on patients. POC and LOC devices, by reducing the need for frequent hospital visits and extensive testing, can help alleviate some of these financial pressures. Patients who can manage their heart failure more efficiently with these devices may experience a better quality of life without the added strain of exorbitant medical bills.

Heart failure often requires ongoing monitoring to ensure the effectiveness of treatment and to prevent readmissions. POC and LOC devices equipped with remote monitoring capabilities allow healthcare providers to track patients' progress and detect potential issues early. This proactive approach can reduce the number of hospital readmissions, which is not only beneficial for patients but also cost-effective for healthcare systems.

As healthcare costs rise, efficient resource allocation becomes essential. POC and LOC devices optimize resource utilization by providing rapid and accurate diagnostics, allowing healthcare providers to focus their resources on patients who require immediate attention. This efficiency contributes to cost containment in healthcare systems.

Increased Patient Empowerment

In today's healthcare landscape, patients are increasingly becoming active participants in their own care. Patient empowerment, driven by technological advancements and

evolving healthcare models, is revolutionizing the way we manage chronic conditions like heart failure.

Patient-centric care places patients at the center of their healthcare journey, empowering them to make informed decisions and take charge of their health. This shift in healthcare philosophy recognizes that engaged patients tend to have better outcomes and experiences. Heart failure patients, in particular, benefit from active participation in their care, and POC and LOC devices play a vital role in enabling this empowerment.

POC and LOC devices provide heart failure patients with the ability to monitor their health in real-time. These devices offer immediate feedback, allowing patients to track vital parameters, such as blood pressure, oxygen levels, and cardiac biomarkers, conveniently at home. This real-time data empowers patients by enabling them to make timely decisions about their care and communicate effectively with healthcare providers.

Empowered heart failure patients are more likely to engage in self-management practices. POC and LOC devices facilitate self-monitoring, helping patients adhere to treatment plans, lifestyle modifications, and medication regimens. By actively participating in their care, patients can better manage their heart failure and improve their overall quality of life.

The rise of telemedicine and remote consultations further empowers heart failure patients. POC and LOC devices can transmit data directly to healthcare providers, allowing for virtual check-ins and consultations. Patients can discuss their health status, receive guidance, and make informed decisions about their care without the need for frequent in-person visits.

Empowered patients are more likely to seek early medical attention when needed. POC and LOC devices enable patients to recognize subtle changes in their health, which can be indicative of worsening heart failure symptoms. Early detection and intervention can prevent hospitalizations and serious complications, ultimately leading to improved outcomes and reduced healthcare costs.

Patient empowerment promotes shared decision-making between patients and healthcare providers. POC and LOC devices empower patients to engage in meaningful discussions with their care teams, share their preferences, and actively participate in creating personalized treatment plans. This collaborative approach results in care that aligns with the patient's values and goals.

Key Market Challenges

Regulatory Hurdles

One of the primary challenges facing this market is navigating complex regulatory requirements. Developing and obtaining regulatory approval for POC and LOC devices can be a lengthy and costly process. Stricter regulations are in place to ensure patient safety and device effectiveness. Complying with these regulations while maintaining innovation and speed to market is a delicate balancing act for manufacturers.

Reimbursement Issues

Reimbursement policies play a crucial role in the adoption of healthcare technologies. POC and LOC devices often face reimbursement challenges, with payers and healthcare systems needing convincing evidence of their cost-effectiveness and clinical utility. Manufacturers must provide robust data and studies to demonstrate the value of their devices, which can be a barrier to market entry.

Adoption and Integration

The successful adoption and integration of POC and LOC devices into existing healthcare systems can be challenging. Healthcare providers need to incorporate these devices seamlessly into their workflows and electronic health records. Resistance to change, staff training, and interoperability issues are common hurdles that must be overcome for widespread adoption.

Key Market Trends

Artificial Intelligence (AI) Integration

AI is revolutionizing healthcare, and its integration into POC and LOC devices is on the horizon. Machine learning algorithms can analyze complex datasets, identify patterns, and assist in early heart failure detection. AI-driven devices are expected to enhance accuracy and speed, resulting in quicker diagnoses and personalized treatment plans.

Multiplex Assays

The next generation of POC and LOC devices will feature multiplex assays, allowing

simultaneous testing for multiple cardiac markers from a single sample. This capability provides a more comprehensive assessment of a patient's cardiac health, reducing the need for multiple tests and streamlining the diagnostic process.

Wearable Technology

Wearable POC and LOC devices are on the horizon, offering continuous monitoring of heart failure patients. These devices can track vital signs, detect early warning signs, and provide real-time feedback to wearers. Wearables will enhance patient convenience and support proactive self-management.

Segmental Insights

Test Type Insights

Notably, in 2022, the proteomic testing segment emerged as the leader in revenue generation. Advances in omics research have spurred investigations into the roles of genomics, proteomics, and metabolomics in cardiovascular events. This research endeavor aims to detect unique biomarkers and develop assays for predicting the risk of a heart attack even before any symptoms manifest. For instance, in April 2022, SomaLogic Inc. achieved a breakthrough by creating a blood test capable of forecasting an individual's risk of experiencing a heart attack, stroke, heart failure, or mortality due to these conditions over the next four years.

Projections indicate that the metabolomics testing segment will experience the most rapid CAGR throughout the forecast period. Common peptides like N-terminal pro-b-type natriuretic peptide (NTproBNP), troponin, and B-type natriuretic peptide (BNP) are frequently examined to monitor cardiovascular events. Notably, Troponin T (TnT) and Troponin I (TnI) stand out as the most specific protein biomarkers associated with myocardial infarction.

Consequently, many companies have set their sights on this biomarker, recognizing it as a pivotal revenue-generating segment. The availability of a relatively high number of commercial Point of Care (POC) devices centered on protein marker testing has contributed significantly to the estimated share of proteomic testing.

Technology Insights

In 2022, the microfluidics sector dominated in terms of revenue share and is poised to

exhibit the most rapid CAGR in the foreseeable future. The escalating concern surrounding mortality and morbidity rates linked to cardiovascular diseases (CVD) has spurred the demand for swift, portable, and cost-effective biosensing devices designed for cardiovascular event screening. Point of Care (POC) biosensors play a pivotal role in the early detection of heart failure, obviating the need for hospital visits and circumventing the laborious and expensive nature of traditional laboratory tests.

Over recent years, there has been a notable uptick in the adoption of microfluidic biosensors, primarily because they facilitate the translation of functional protocols typically employed in central laboratories into compact chips, thus enabling miniaturization. Furthermore, they offer several advantages, including reduced consumption of reagents and samples and expedited turnaround times.

Consequently, the utilization of paper-based 3D microfluidics in POC applications has witnessed substantial growth, owing to its proficiency in managing liquids at an advanced level. These factors have resulted in microfluidic technology securing the largest share of revenue. Anticipated advancements in this technique are poised to drive this segment in the forthcoming years.

Regional Insights

In 2022, North America asserted its dominance in the market, securing the highest revenue share. This was primarily attributed to significant contributions from key market players based in the United States, resulting in substantial organic revenue growth within the global market for point-of-care (POC) and lab-on-a-chip (LOC) devices for heart failure. To illustrate, in December 2021, Quidel Corporation and Ortho Clinical Diagnostics Holdings plc entered into a business combination agreement, enhancing patients' access to a wide array of medical products, including immunohematology, immunoassay, molecular diagnostics, clinical chemistry, donor screening, and point-of-care diagnostics.

Conversely, there is a rising demand for diagnostic services in Asian nations. Asia Pacific is anticipated to exhibit the most rapid CAGR during the forecast period, spanning from 2024 to 2030. This growth is underpinned by a shift in focus from infectious diseases to chronic ailments such as acute coronary syndrome, myocardial infarction, and cardiac ischemia. Additionally, as medical standards continue to improve and state-of-the-art medical infrastructure develops, Asian countries are becoming increasingly attractive to numerous global diagnostic firms seeking to expand their business operations.

Key Market Players

Abbott Laboratories Inc

Siemens Healthineers AG

Danaher Corp

Instrumentation Laboratory Co

Hoffmann-La Roche Ltd

bioMerieux Inc

Abaxis Inc

Quidel Corp

Jant Pharmacal Corp

Trinity Biotech plc

Report Scope:

In this report, the Global Heart Failure POC & LOC Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Heart Failure POC & LOC Devices Market, By Test Type:

Genomic Testing

Metabolomic Testing

Proteomic Testing

Heart Failure POC & LOC Devices Market, By Technology:

Array-based Systems

Microfluidics

Heart Failure POC & LOC Devices Market, By End-user:

Assisted Living Healthcare Facilities

Clinics

Home

Hospitals

Laboratory

Heart Failure POC & LOC Devices Market, By Region:

North America

United States

Canada

Mexico

Europe

Germany

United Kingdom

France

Italy

Spain

Asia-Pacific

China

Japan

India

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Heart Failure POC & LOC Devices Market.

Available Customizations:

Global Heart Failure POC & LOC Devices market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The

following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Test Type (Genomic Testing, Metabolomic Testing, Proteomic Testing)
 - 5.2.2. By Technology (Array-based Systems, Microfluidics)
 - 5.2.3. By End-user (Assisted Living Healthcare Facilities, Clinics, Home, Hospitals, Laboratory)

- 5.2.4. By Region
- 5.2.5. By Company (2022)
- 5.3. Product Market Map
 - 5.3.1. By Test Type
 - 5.3.2. By Technology
 - 5.3.3. By End-user
 - 5.3.4. By Region

6. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET OUTLOOK

- 6.1. Market Size & Forecast
 - 6.1.1. By Value
- 6.2. Market Share & Forecast
 - 6.2.1. By Test Type (Genomic Testing, Metabolomic Testing, Proteomic Testing)
 - 6.2.2. By Technology (Array-based Systems, Microfluidics)
 - 6.2.3. By End-user (Assisted Living Healthcare Facilities, Clinics, Home, Hospitals, Laboratory)
 - 6.2.4. By Country
- 6.3. North America: Country Analysis
 - 6.3.1. United States Heart Failure POC & LOC Devices Market Outlook
 - 6.3.1.1. Market Size & Forecast
 - 6.3.1.1.1. By Value
 - 6.3.1.2. Market Share & Forecast
 - 6.3.1.2.1. By Test Type
 - 6.3.1.2.2. By Technology
 - 6.3.1.2.3. By End-user
 - 6.3.2. Canada Heart Failure POC & LOC Devices Market Outlook
 - 6.3.2.1. Market Size & Forecast
 - 6.3.2.1.1. By Value
 - 6.3.2.2. Market Share & Forecast
 - 6.3.2.2.1. By Test Type
 - 6.3.2.2.2. By Technology
 - 6.3.2.2.3. By End-user
 - 6.3.3. Mexico Heart Failure POC & LOC Devices Market Outlook
 - 6.3.3.1. Market Size & Forecast
 - 6.3.3.1.1. By Value
 - 6.3.3.2. Market Share & Forecast
 - 6.3.3.2.1. By Test Type
 - 6.3.3.2.2. By Technology

6.3.3.2.3. By End-user

7. EUROPE HEART FAILURE POC & LOC DEVICES MARKET OUTLOOK

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Test Type (Genomic Testing, Metabolomic Testing, Proteomic Testing)

7.2.2. By Technology (Array-based Systems, Microfluidics)

7.2.3. By End-user (Assisted Living Healthcare Facilities, Clinics, Home, Hospitals, Laboratory)

7.2.4. By Country

7.3. Europe: Country Analysis

7.3.1. Germany Heart Failure POC & LOC Devices Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Test Type

7.3.1.2.2. By Technology

7.3.1.2.3. By End-user

7.3.2. United Kingdom Heart Failure POC & LOC Devices Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Test Type

7.3.2.2.2. By Technology

7.3.2.2.3. By End-user

7.3.3. France Heart Failure POC & LOC Devices Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Test Type

7.3.3.2.2. By Technology

7.3.3.2.3. By End-user

7.3.4. Italy Heart Failure POC & LOC Devices Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Test Type

- 7.3.4.2.2. By Technology
- 7.3.4.2.3. By End-user
- 7.3.5. Spain Heart Failure POC & LOC Devices Market Outlook
 - 7.3.5.1. Market Size & Forecast
 - 7.3.5.1.1. By Value
 - 7.3.5.2. Market Share & Forecast
 - 7.3.5.2.1. By Test Type
 - 7.3.5.2.2. By Technology
 - 7.3.5.2.3. By End-user

8. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET OUTLOOK

- 8.1. Market Size & Forecast
 - 8.1.1. By Value
- 8.2. Market Share & Forecast
 - 8.2.1. By Test Type (Genomic Testing, Metabolomic Testing, Proteomic Testing)
 - 8.2.2. By Technology (Array-based Systems, Microfluidics)
 - 8.2.3. By End-user (Assisted Living Healthcare Facilities, Clinics, Home, Hospitals, Laboratory)
 - 8.2.4. By Country
- 8.3. Asia-Pacific: Country Analysis
 - 8.3.1. China Heart Failure POC & LOC Devices Market Outlook
 - 8.3.1.1. Market Size & Forecast
 - 8.3.1.1.1. By Value
 - 8.3.1.2. Market Share & Forecast
 - 8.3.1.2.1. By Test Type
 - 8.3.1.2.2. By Technology
 - 8.3.1.2.3. By End-user
 - 8.3.2. Japan Heart Failure POC & LOC Devices Market Outlook
 - 8.3.2.1. Market Size & Forecast
 - 8.3.2.1.1. By Value
 - 8.3.2.2. Market Share & Forecast
 - 8.3.2.2.1. By Test Type
 - 8.3.2.2.2. By Technology
 - 8.3.2.2.3. By End-user
 - 8.3.3. India Heart Failure POC & LOC Devices Market Outlook
 - 8.3.3.1. Market Size & Forecast
 - 8.3.3.1.1. By Value
 - 8.3.3.2. Market Share & Forecast

- 8.3.3.2.1. By Test Type
- 8.3.3.2.2. By Technology
- 8.3.3.2.3. By End-user
- 8.3.4. Australia Heart Failure POC & LOC Devices Market Outlook
 - 8.3.4.1. Market Size & Forecast
 - 8.3.4.1.1. By Value
 - 8.3.4.2. Market Share & Forecast
 - 8.3.4.2.1. By Test Type
 - 8.3.4.2.2. By Technology
 - 8.3.4.2.3. By End-user
- 8.3.5. South Korea Heart Failure POC & LOC Devices Market Outlook
 - 8.3.5.1. Market Size & Forecast
 - 8.3.5.1.1. By Value
 - 8.3.5.2. Market Share & Forecast
 - 8.3.5.2.1. By Test Type
 - 8.3.5.2.2. By Technology
 - 8.3.5.2.3. By End-user

9. SOUTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET OUTLOOK

- 9.1. Market Size & Forecast
 - 9.1.1. By Value
- 9.2. Market Share & Forecast
 - 9.2.1. By Test Type (Genomic Testing, Metabolomic Testing, Proteomic Testing)
 - 9.2.2. By Technology (Array-based Systems, Microfluidics)
 - 9.2.3. By End-user (Assisted Living Healthcare Facilities, Clinics, Home, Hospitals, Laboratory)
 - 9.2.4. By Country
- 9.3. South America: Country Analysis
 - 9.3.1. Brazil Heart Failure POC & LOC Devices Market Outlook
 - 9.3.1.1. Market Size & Forecast
 - 9.3.1.1.1. By Value
 - 9.3.1.2. Market Share & Forecast
 - 9.3.1.2.1. By Test Type
 - 9.3.1.2.2. By Technology
 - 9.3.1.2.3. By End-user
 - 9.3.2. Argentina Heart Failure POC & LOC Devices Market Outlook
 - 9.3.2.1. Market Size & Forecast
 - 9.3.2.1.1. By Value

- 9.3.2.2. Market Share & Forecast
 - 9.3.2.2.1. By Test Type
 - 9.3.2.2.2. By Technology
 - 9.3.2.2.3. By End-user
- 9.3.3. Colombia Heart Failure POC & LOC Devices Market Outlook
 - 9.3.3.1. Market Size & Forecast
 - 9.3.3.1.1. By Value
 - 9.3.3.2. Market Share & Forecast
 - 9.3.3.2.1. By Test Type
 - 9.3.3.2.2. By Technology
 - 9.3.3.2.3. By End-user

10. MIDDLE EAST AND AFRICA HEART FAILURE POC & LOC DEVICES MARKET OUTLOOK

- 10.1. Market Size & Forecast
 - 10.1.1. By Value
- 10.2. Market Share & Forecast
 - 10.2.1. By Test Type (Genomic Testing, Metabolomic Testing, Proteomic Testing)
 - 10.2.2. By Technology (Array-based Systems, Microfluidics)
 - 10.2.3. By End-user (Assisted Living Healthcare Facilities, Clinics, Home, Hospitals, Laboratory)
 - 10.2.4. By Country
- 10.3. MEA: Country Analysis
 - 10.3.1. South Africa Heart Failure POC & LOC Devices Market Outlook
 - 10.3.1.1. Market Size & Forecast
 - 10.3.1.1.1. By Value
 - 10.3.1.2. Market Share & Forecast
 - 10.3.1.2.1. By Test Type
 - 10.3.1.2.2. By Technology
 - 10.3.1.2.3. By End-user
 - 10.3.2. Saudi Arabia Heart Failure POC & LOC Devices Market Outlook
 - 10.3.2.1. Market Size & Forecast
 - 10.3.2.1.1. By Value
 - 10.3.2.2. Market Share & Forecast
 - 10.3.2.2.1. By Test Type
 - 10.3.2.2.2. By Technology
 - 10.3.2.2.3. By End-user
 - 10.3.3. UAE Heart Failure POC & LOC Devices Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Test Type

10.3.3.2.2. By Technology

10.3.3.2.3. By End-user

10.3.4. Kuwait Heart Failure POC & LOC Devices Market Outlook

10.3.4.1. Market Size & Forecast

10.3.4.1.1. By Value

10.3.4.2. Market Share & Forecast

10.3.4.2.1. By Test Type

10.3.4.2.2. By Technology

10.3.4.2.3. By End-user

11. MARKET DYNAMICS

11.1. Drivers

11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Recent Development

12.2. Mergers & Acquisitions

12.3. Product Launches

13. PORTER'S FIVE FORCES ANALYSIS

13.1. Competition in the Industry

13.2. Potential of New Entrants

13.3. Power of Suppliers

13.4. Power of Customers

13.5. Threat of Substitute Products

14. COMPETITIVE LANDSCAPE

14.1. Business Overview

14.2. Product Offerings

14.3. Recent Developments

14.4. Financials (As Reported)

14.5. Key Personnel

14.6. SWOT Analysis

14.6.1. Abbott Laboratories Inc

14.6.2. Siemens Healthineers AG

14.6.3. Danaher Corp

14.6.4. Instrumentation Laboratory Co

14.6.5. Hoffmann-La Roche Ltd

14.6.6. bioMerieux Inc

14.6.7. Abaxis Inc

14.6.8. Quidel Corp

14.6.9. Jant Pharmacal Corp

14.6.10. Trinity Biotech plc

15. STRATEGIC RECOMMENDATIONS

16. ABOUT US & DISCLAIMER

I would like to order

Product name: Heart Failure POC & LOC Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Test Type (Genomic Testing, Metabolomic Testing, Proteomic Testing), By Technology (Array-based Systems, Microfluidics), By End-user (Assisted Living Healthcare Facilities, Clinics, Home, Hospitals, Laboratory), By Region, By Competition Forecast & Opportunities, 2018-2028F

Product link: <https://marketpublishers.com/r/HFCB299483C1EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HFCB299483C1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970